Payment overview · 2025
General Payments
$258.21
12 reported records · 8 companies
Healthcare provider profile · identity verified
Stefanie Ramirez
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · FREEPORT, NY · NPI 1295222461
Verified facts
What the public records show
CMS Open Payments records show Stefanie Ramirez received $258.21 in general payments during 2025 across 12 reported records.
PFIZER INC. accounted for 27.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $69.62 | 27.0% | 3 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $42.48 | 16.4% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$31.17 | 12.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.60 | 11.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $28.44 | 11.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.77 | 8.0% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $18.56 | 7.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.57 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $258.21 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $69.62 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $69.62 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $69.62 | 3 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $42.48 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $31.17 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.60 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $28.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.77 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 37 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 206 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 115 |
| Metformin Hcl | Metformin Hcl | 198 | 94 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 64 |
| Losartan Potassium | Losartan Potassium | 152 | 79 |
| Omeprazole | Omeprazole | 141 | 72 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 115 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 113 | 63 |
| Simvastatin | Simvastatin | 110 | 53 |
| Lisinopril | Lisinopril | 107 | 58 |
| Diclofenac Sodium | Diclofenac Sodium | 93 | 48 |
| Gabapentin | Gabapentin | 93 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 90 | 41 |
| Famotidine | Famotidine | 80 | 34 |
| Alendronate Sodium | Alendronate Sodium | 78 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 76 | 43 |
| Enalapril Maleate | Enalapril Maleate | 74 | 27 |
| Jardiance | Empagliflozin | 67 | 37 |
| Glipizide | Glipizide | 66 | 29 |
| Atenolol | Atenolol | 62 | 32 |
| Januvia | Sitagliptin Phosphate | 62 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 26 |
| Ammonium Lactate | Ammonium Lactate | 56 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 48 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 48 | 26 |
| Montelukast Sodium | Montelukast Sodium | 47 | 22 |
| Glimepiride | Glimepiride | 46 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 44 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 42 | 24 |
| Azithromycin | Azithromycin | 39 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 39 | 19 |
| Meclizine Hcl | Meclizine Hcl | 39 | 25 |
| Meloxicam | Meloxicam | 36 | 18 |
| Furosemide | Furosemide | 35 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 34 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | 22 |
| Valsartan | Valsartan | 34 | 15 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 32 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 17 |
| Nystatin | Nystatin | 30 | 15 |
| Carvedilol | Carvedilol | 29 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | 14 |
| Vascepa | Icosapent Ethyl | 27 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | 14 |
| Naproxen | Naproxen | 25 | 16 |
| Farxiga | Dapagliflozin Propanediol | 24 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | 14 |
| Ibuprofen | Ibuprofen | 23 | 13 |
| Ketoconazole | Ketoconazole | 23 | 13 |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 21 | suppressed |
| Ozempic | Semaglutide | 21 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | 11 |
| Hydrocortisone | Hydrocortisone | 20 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 15 |
| Prednisone | Prednisone | 19 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | 11 |
| Tradjenta | Linagliptin | 19 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Allopurinol | Allopurinol | 17 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 15 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | 12 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $258.21 · 12 records | PFIZER INC. | ABRYSVO, ACCRUFER, COMIRNATY, JARDIANCE, Kerendia, Leqembi, MINIMED 780G, OTEZLA, Ozempic, PREVNAR 20, REPATHA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error